bpc-157 safety human case reports evidence clinical trials and the Difference Between an Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 bpc-157 safety adverse effects humans

PMID: 21030672 Tissus mous musculo-squelettiques Gwyer D et al

First, they studied a topical eye drop of the full-length protein for an ocular-surface condition not a systemic injectable, and not the LKKTETQ fragment sold as TB-500

The mechanisms by which inflammation affects tight junction structure and function and transcellular mechanisms such as endocytosis are largely unknown, although reproducible correlations have been observed between the severity of experimental and clinical disease and on the one hand and transepithelial electrical resistance, transport of paracellular markers, and systemic LPS concentrations and on the other [42, 86]

The layered structure supports controlled composition of ingredients while eliminating the need for traditional mixing, encapsulation, or other complex preparation methods

CPT 96374, by contrast, covers intravenous (IV) push administration where the substance is delivered directly into a vein, typically by a syringe, and the administering provider must be present during the entire infusion

What exists is mechanistic plausibility, preclinical animal data, and observational reports from research settings